Golf,

I agree completely - just being cautious in my reporting.  If there are good outcomes here, and the message is clearly that there are, the strong safety profile and the fact that apabetalone can be used to address so many correlated morbidities with limited existing treatment options make it quite possible (IMO) that it can gain approval without further trials, bolt-on or otherwise.  

One of the advantages of spending so damn long developing this drug is that RVX has made good use of the time collecting and analyzing a lot of data to support that apabetalone is a safe and effective treatment for the host of chronic diseases that come with age.  These are the scourge of our aging western populations - I'm sure that upcoming generations would rather pay for our drug treatment than for our bypass surgery, dialysis, institutionalization for dementia, etc.  Not to mention that we would prefer the drug treatment too!

Jupe